Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.0%

13 terminated/withdrawn out of 93 trials

Success Rate

79.0%

-7.5% vs industry average

Late-Stage Pipeline

5%

5 trials in Phase 3/4

Results Transparency

29%

14 of 49 completed trials have results

Key Signals

11 recruiting14 with results8 terminated5 withdrawn

Enrollment Performance

Analytics

N/A
66(76.7%)
Phase 1
8(9.3%)
Phase 2
5(5.8%)
Phase 3
4(4.7%)
Early Phase 1
2(2.3%)
Phase 4
1(1.2%)
86Total
N/A(66)
Phase 1(8)
Phase 2(5)
Phase 3(4)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (93)

Showing 20 of 93 trials
NCT06974916Not ApplicableRecruiting

EMBRACE Tremor BiFUS

Role: lead

NCT05317858Phase 3Recruiting

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

Role: lead

NCT04579692Not ApplicableActive Not Recruiting

MR Guided Focused Ultrasound (FUS) for the Treatment of Trigeminal Neuralgia

Role: collaborator

NCT03028246Not ApplicableRecruiting

A Feasibility Safety Study of Benign Centrally-Located Intracranial Tumors in Pediatric and Young Adult Subjects

Role: lead

NCT04197921Not ApplicableRecruiting

Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Use Disorders (SUDs)

Role: lead

NCT04002596Not ApplicableCompleted

Safety and Initial Effectiveness of Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease

Role: lead

NCT04559685Early Phase 1Terminated

Study of Sonodynamic Therapy in Participants With Recurrent High-Grade Glioma

Role: collaborator

NCT06584383Not ApplicableActive Not Recruiting

A Prospective, Randomized, Controlled Trial to Test Safety and Effectiveness of Unilateral Exablate MR-guided Focused Ultrasound Subthalamotomy in Patients With Early-Stage Parkinson's Disease

Role: lead

NCT05089786Not ApplicableWithdrawn

Echo-Focusing in Patients With Treatment-Resistant Neurologic and Psychiatric Indications (EF001)

Role: lead

NCT05615623Phase 1Active Not Recruiting

Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG

Role: lead

NCT02246374Not ApplicableCompleted

ExAblate Transcranial MRgFUS of the Subthalamic Nucleus for Treatment of Parkinson's Disease

Role: lead

NCT05630209Phase 1Active Not Recruiting

Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)

Role: lead

NCT04998864Completed

Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption in GBM Patients

Role: lead

NCT03454425Not ApplicableCompleted

A Study to Evaluate the Safety and Efficacy of ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features

Role: lead

NCT05539196Recruiting

A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications

Role: lead

NCT03714243Not ApplicableCompleted

Blood Brain Barrier Disruption (BBBD) Using MRgFUS in the Treatment of Her2-positive Breast Cancer Brain Metastases

Role: lead

NCT04649554Not ApplicableTerminated

Study of MRgFUS Exablate Treatment Following the Neuropathic Pain

Role: lead

NCT03321487Not ApplicableCompleted

Blood-Brain Barrier Opening Using MR-Guided Focused Ultrasound in Patients With Amyotrophic Lateral Sclerosis

Role: lead

NCT03964272Not ApplicableCompleted

A Feasibility Study on the Safety and Preliminary Efficacy of Bilateral Subthalamotomy Using MRgFUS for Treatment of PD

Role: lead

NCT03551249Not ApplicableCompleted

Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption

Role: lead